Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Takeda Pharmaceutical Co's change in inventory for the fiscal year that ended in Mar. 2026 was $-386 Mil. It means Takeda Pharmaceutical Co's inventory
increased by $386 Mil
from Mar. 2025 to Mar. 2026 .
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Takeda Pharmaceutical Co's Days Inventory for the quarter that ended in Jun. 2026 was 321.12.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Takeda Pharmaceutical Co's Inventory Turnover for the quarter that ended in Jun. 2026 was 0.28.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Takeda Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Jun. 2026 was 1.17.
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Takeda Pharmaceutical Co's Inventory to Revenue for the quarter that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co Change In Inventory Related Terms
Takeda Pharmaceutical Co Change In Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Takeda Pharmaceutical Co Change In Inventory Chart
Takeda Pharmaceutical Co Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-322 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Inventory of $-322 Mil mean?
Takeda Pharmaceutical Co (TAK) has a Change In Inventory of $-322 Mil as of Jun. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Change In Inventory too high?
Takeda Pharmaceutical Co's current Change In Inventory is $-322 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Change In Inventory compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Change In Inventory of $-322 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Drug Manufacturers company?
A good Change In Inventory depends on the Drug Manufacturers industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Change In Inventory is $-322 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TAK) is currently considered Modestly Overvalued. The stock's GF Value™ is $14.13, compared to a current price of $17.09 — trading 20.9% above its estimated fair value. The current Change In Inventory is $-322 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 76/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TAK), the current Change In Inventory is $-322 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (TAK) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of $17.09 is trading 20.9% above its estimated GF Value™ of $14.13.
GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for TAK:
Change In Inventory: $-322 Mil
GF Value™: $14.13 vs. price of $17.09 (20.9% above fair value)
No single metric tells the full story. See the TAK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
76GF Score
Get the complete analysis for TAK
Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TAK has been successfully added to your 
